Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 18/20 | 0.74 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.74 |
| ▸ | CDC37 | Q16543 | 7/20 | 0.71 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4130032 | 0.83 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1CDC37HSP90B1 | |
| SCHEMBL4130050 | 0.83 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1CDC37 | |
| SCHEMBL4127512 | 0.83 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1CDC37HSP90B1 | |
| SCHEMBL4124842 | 0.82 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1CDC37HSP90B1 | |
| SCHEMBL12454188 | 0.81 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1CDC37HSP90B1 | |
| SCHEMBL4129503 | 0.81 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1CDC37HSP90B1 | |
| SCHEMBL14085058 | 0.81 | HSP90AA1 (0.75) | HSP90AA1HSP90AB1CDC37HSP90B1 | |
| SCHEMBL4133476 | 0.81 | HSP90AA1 (0.75) | HSP90AA1HSP90AB1CDC37HSP90B1 | |
| SCHEMBL4130259 | 0.79 | HSP90AA1 (0.58) | HSP90AA1HSP90AB1CDC37HSP90B1 | |
| SCHEMBL4136279 | 0.79 | HSP90AA1 (0.79) | HSP90AA1HSP90AB1CDC37 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192687-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192687-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192687-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023006993-A1 | FUSED AMINO PYRIDINE OR PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CONGENITAL CENTRAL HYPOVENTILATION SYNDROME | ATMOSR (FR) | 2023-02-02 | — | — | WO | disclosed |
| US-11560377-B2 | Fused amino pyridine as HSP90 inhibitors | Guris, Inc. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11560377-B2 | Fused amino pyridine as HSP90 inhibitors | Guris, Inc. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210292317-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210292317-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-10844056-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-10844056-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-8324240-B2 | Fused amino pyridine as HSP90 inhibitors | CURIS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120237508-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. | 2012-09-20 | — | — | US | disclosed |
| US-20120237508-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. | 2012-09-20 | — | — | US | disclosed |
| US-20120237508-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. | 2012-09-20 | — | — | US | disclosed |
| EP-2069324-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | Curis, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008115719-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008115719-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234314-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
| US-20080234314-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
| US-20080234314-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120237508-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | HSP90AA1 4/4885HSP90AB1 2/4885CDC37 5/4885 |
| US-20230192687-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | HSP90AA1 4/4885HSP90AB1 2/4885CDC37 5/4885 |
| US-20080234314-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | HSP90AA1 4/4885HSP90AB1 2/4885CDC37 5/4885 |
| US-20210292317-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | HSP90AA1 4/4885HSP90AB1 2/4885CDC37 5/4885 |
| US-11560377-B2 | Fused amino pyridine as HSP90 inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | HSP90AA1 4/4885HSP90AB1 2/4885CDC37 5/4885 |
| US-10844056-B2 | Fused amino pyridine as HSP90 inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | HSP90AA1 4/4885HSP90AB1 2/4885CDC37 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.